Given that DMI and 4OI, which both also drive NRF2 accumulation, exerted similar inhibitory effects on nigericin‐ and LPC‐induced NLRP3 activation, it is possible that these itaconate derivatives may also offer therapeutic potential in the development of new inhibitors for the treatment of multiple sclerosis. Here, NLRP3 is linked to multiple sclerosis.